Roger Sawhney insider trades

Open-market stock purchases and sales by Roger Sawhney, Director at Arbutus Biopharma Corp, from SEC Form 4 filings since Aug 3, 2021.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -99%.

Recent trades

DateStockTradeValue
Oct 1, 2026ABUS Arbutus Biopharma CorpSold (not open market)$85.7K
Sep 18, 2026ABUS Arbutus Biopharma CorpSold (not open market)$510K
Sep 18, 2026ABUS Arbutus Biopharma CorpBought (not open market)—
Sep 18, 2026ABUS Arbutus Biopharma CorpBought (not open market)—
Jun 8, 2026ABUS Arbutus Biopharma CorpBought (not open market)—
May 21, 2026ACTU Actuate Therapeutics, IncBought (not open market)—

Companies traded

  • ABUS Arbutus Biopharma Corp: other filings, last Oct 1, 2026
  • ACTU Actuate Therapeutics, Inc: other filings, last May 21, 2026
  • ALIM Alimera Sciences Inc: other filings, last Feb 25, 2023
  • OMGA Omega Therapeutics, Inc: 1 buy, last Mar 9, 2022

Get free alerts when Roger Sawhney files a new trade →